pcn poster

Posters

Successful Buprenorphine/Naloxone High-dose Induction in Pregnancy

Medication for opioid use disorder (OUD) with methadone or buprenorphine/naloxone is recommended for pregnant women with OUD. Traditional buprenorphine/naloxone induction requires patient...

Arjun Bhatt , BA;

10/26/2023

SURWEY Study of Solriamfetol: Initiation, Titration, Safety, Efficacy, and Follow-Up Experience for Patients with OSA in Germany

This real-world study examined initiation strategies and subsequent outcomes for solriamfetol (Sunosi®), a wake-promoting agent used to treat excessive daytime sleepiness (EDS) in obstruc...

Charlotte Wincott , PhD;

10/26/2023

Shaping Psychiatric Pharmacy Through Stewardship and Standardized Outcomes

The American Association of Psychiatric Pharmacists (AAPP) has sought to operationalize the concept of psychotropic stewardship through formalizing a consensus-based set of outcomes and m...

Jonathan Lister , PharmD, BCPP;

10/26/2023

Safety and Efficacy of Low-Sodium Oxybate in Participants With Narcolepsy With and Without Psychiatric Comorbidities: Subgroup Analysis of a Phase 3 Clinical Trial

This study assessed safety and efficacy of low-sodium oxybate (LXB) in participants with narcolepsy both with and without comorbid psychiatric disorders in a phase 3 clinical study. Safet...

Craig Chepke , MD, DFAPA;

10/26/2023

Safety and Tolerability of Zuranolone 50 mg in Patients with Major Depressive Disorder: Results from the Phase 3 WATERFALL and CORAL Studies

Zuranolone 50 mg initiated alone (WATERFALL Study) or co-initiated with a standard-of-care antidepressant (CORAL Study) was well-tolerated in adults with major depressive disorder. In WAT...

Cole Brown , MD;

10/26/2023

Screening for Obsessive Compulsive Disorder among college students using the Obsessive Compulsive Inventory-4

This study aimed to assess the efficacy of the Obsessive Compulsive Inventory questionnaire (OCI-4), a four-item OCD screening tool used to detect OCD, in a cohort of college students. Th...

10/26/2023

Real-World Antipsychotic and Vesicular Monoamine Transporter Type 2 Inhibitor Treatment Patterns in Patients Newly Diagnosed With Tardive Dyskinesia

Antipsychotic (AP) and vesicular monoamine transporter type 2 inhibitor (VMAT2i) treatment patterns post-tardive dyskinesia (TD) diagnosis are unclear. Deutetrabenazine (DTBZ) is a VMAT2i...

Marko Mychaskiw , PhD;

10/26/2023

Real-World Antipsychotic Treatment Modification With and Without Deutetrabenazine in Patients Newly Diagnosed With Tardive Dyskinesia

Tardive dyskinesia (TD) management includes antipsychotic (AP) dose modification/discontinuation, often leaving underlying psychiatric conditions undertreated. Deutetrabenazine (DTBZ) is ...

Marko Mychaskiw , PhD;

10/26/2023

Real-World Effectiveness of Deutetrabenazine When Initiated Using a 4-Week Patient Titration Kit: Interim Results of the START Study

START is an ongoing, noninterventional, prospective, single-arm, 2-cohort (tardive dyskinesia [TD] and Huntington disease) study evaluating the effectiveness of deutetrabenazine initiated...

Andrew J. Cutler , MD;

10/26/2023

Real-World Observational Study of Implementation and Evaluation of the Pathway Platform: A Digitally Enabled Care Pathway to Improve Depression Management in Primary Care

The Pathway Platform supports MBC for patients with MDD by integrating a patient-facing app with EHR. This real-world Pathway Platform implementation study in primary care demonstrated si...

Christopher Blair , MS;

10/26/2023

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products